ITP and TTP: interpreting evidence in light of patient values.
In this issue of Blood, data presented by Zhou et al and Lim et al on the use of rituximab (RTX) to treat immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP), respectively, illuminate the importance of considering patient values and preferences in the interpretation of clinical evidence.
UNIVERSITY OF PENNSYLVANIA.
Adam
A
Cuker
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000628:therapy*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000628:therapy*; D013926:Thrombopoietin / Q000008:administration & dosage*
D058846:Antibodies, Monoclonal, Murine-Derived; D013926:Thrombopoietin